Investor Tom Hulick highlights Broadcom's AI-focused, power-efficient ASICs and Eli Lilly's GLP-1 drug pipeline, while StockStory cautions against uncritical acceptance of Wall Street price targets.
Investor Tom Hulick highlights Broadcom's AI-focused, power-efficient ASICs and Eli Lilly's GLP-1 drug pipeline, while StockStory cautions against uncritical acceptance of Wall Street price targets.